1. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
2. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
5. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
6. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period
distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol.
2011;40(4):964–70.
7. Stratégie de l’OMS pour mettre fin à la tuberculose. Organisation mondiale de la Santé [site Web] (http://www.who.int/tb/strategy/fr/, consulté le 15 mars 2020).
8. Stratégie et cibles de la lutte antituberculeuse après 2015. Organisation mondiale de la Santé [site Web] ;2013 (https://www.who.int/tb/post2015_strategy/fr/, consulté le 15 mars 2020).
9. Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, consulté le 15 mars 2020) (https://www.who.int/mediacentre/news/releases/2014/tb-elimination/fr/).
10. Rapport 2019 sur la tuberculose dans le monde. Genève : Organisation mondiale de la Santé ; 2019 (https://www.who.int/tb/publications/global_report/fr/, consulté le 15 mars 2020).
11. Political declaration of the High-Level Meeting of the General Assembly on the Fight Against Tuberculosis. UN General Assembly 73rd session; 2018 (http://digitallibrary.un.org/record/1649568, consulté le 15 mars 2020).
12. WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/biTCTream/handle/10665/331170/9789240001503-eng.pdf, consulté le 15 mars 2020).
13. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, consulté le 15 mars 2020).
14. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
15. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
16. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714
17. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
18. Directives pour l’intensification du dépistage de la tuberculose et l’administration du traitement préventif à l’isoniazide chez les personnes vivant avec le VIH dans un contexte de ressources limitées. Genève : Organisation mondiale de la Santé ; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44781/9789242500707_fre. pdf?sequence=1, consulté le 15 mars 2020).
19. Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
20. Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
21. Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
22. Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
23. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
24. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
25. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
26. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
27. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
28. Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
29. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrenttuberculosis- relapse-versus-reinfection-and-related-risk-factors, consulté le 15 mars 2020).
30. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, consulté le 15 mars 2020).
31. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middleincome countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/ contact_investigation2012/en/, consulté le 15 mars 2020).
32. WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infectionprevention- 2019/en/, consulté le 15 mars 2020).
33. WHO Policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_ eng_Annexes.pdf, accessed 15 March 2020).
34. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and metaanalysis. Eur Respir J. 2013;41(1):140–156.
35. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
36. Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
37. Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
38. Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
39. Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, consulté le 15 mars 2020).
40. Infection tuberculeuse latente : Lignes directrices unifiées et actualisées pour la prise en charge programmatique. Genève : Organisation mondiale de la Santé ; 2018 (https://apps.who.int/iris/bitstream/handle/10665/312054/9789242550238-fre.pdf?ua=1, consulté le 15 mars 2020).
41. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https://www.who.int/tb/publications/chest-radiography/en/, consulté le 15 mars 2020).
42. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
43. TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, consulté le 15 mars 2020).
44. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, consulté le 15 mars 2020).
45. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
46. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
47. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, consulté le 16 mars 2020).
48. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
49. Directives pour la prise en charge de l’infection tuberculeuse latente. Genève : Organisation mondiale de la Santé ; 2015 (https://apps.who.int/iris/bitstream/handle/10665/137335/9789242548907_fre.pdf?sequence=1, consulté le 16 mars 2020).
50. Lignes directrices concernant la prise en charge de la tuberculose chez l’enfant dans le cadre des programmes nationaux ce lute contre la tuberculose. Genève : Organisation mondiale de la Santé ; 2014 (https://apps.who.int/iris/bitstream/handle/10665/251469/9789242548747-fre.pdf?sequence=1&isAllowed=y, consulté le 16 mars 2020).
51. January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/ documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, consulté le 16 mars 2020).
52. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
53. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
54. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
55. Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [website] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicineto- prevent-tb/#en, consulté le 16 mars 2020).
56. Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
57. Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [website] 2019 (https://www.impaact4tb.org/catalyzing-pediatrictuberculosis- innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, consulté le 16 mars 2020).
58. TPT implementation tools. IMPAACT4TB [website] 2019 (https://www.impaact4tb.org/3hp-documents/, consulté le 16 mars 2020).
59. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
60. Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
61. Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
62. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
63. Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
64. Toman K, Frieden TR. La tuberculose d’après K. Toman : dépistage, chimiothérapie et surveillance – questions et réponses. 2ème édition. Genève : Organisation mondiale de la Santé ; 2004. (https://www.challengetb. org/publications/tools/ua/Toman_Francais.pdf)
65. McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
66. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8. 67. Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
68. Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
69. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
70. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
71. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
72. Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
73. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
74. Lignes directrices de l’OMS pour le traitement de la tuberculose sensible aux médicaments et la prise en charge du patient, mise à jour 2017. Genève : Organisation mondiale de la Santé ; 2017 (https://www.who.int/tb/publications/2017/DS_TB_treatment_factsheet_fr.pdf?ua=1, consulté le 18 mars 2020).
75. Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://www.differentiatedcare.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, consulté le 18 mars 2020).
76. Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [website] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care/, consulté le 18 mars 2020).
77. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
78. Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
79. Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, consulté le 18 mars 2020).
80. Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, consulté le 18 mars 2020).
81. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
82. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
83. Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
84. Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, consulté le 18 mars 2020).
85. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
86. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
87. McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
88. Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
89. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
90. Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
91. Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, consulté le 18 mars 2020).
92. Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
93. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
94. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
95. Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-thetreatment- of-tb-infection/, consulté le 18 mars 2020).
96. Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
97. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
98. Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
99. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
100. Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, consulté le 18 mars 2020).
101. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
102. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
103. Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, consulté le 18 mars 2020).
104. Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, consulté le 18 mars 2020).
105. William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
106. HIV drug interaction checker. University of Liverpool [website] (https://www.hiv-druginteractions.org/checker, consulté le 18 mars 2020).
107. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [website]; 2018 (http://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/, accessed 18 March 2020).
108. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
109. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
110. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
111. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
112. Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sessions/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir, consulté le 18 mars 2020).
113. López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
114. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
115. Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, consulté le 18 mars 2020).
116. Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, consulté le 18 mars 2020).
117. Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
118. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
119. Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015;60(4):639–45.
120. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301–10.
121. Kyaw NTT, Kumar AM, Kyaw KWY, Satyanarayana S, Magee MJ, Min AC, et al. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality. Int Union Tuberc Lung Dis. 2019;23(3):322–30.
122. Wisaksana R, Hartantri Y, Lestari M, Azzahra D, Karjadi T, Yunihastuti E, et al. Benefit of isoniazid preventive therapy to reduce incident TB, mortality and loss to follow-up in Indonesian five-years cohort. 22nd International AIDS Conference (AIDS 2018); Amsterdam, Netherlands | 23–27 July 2018 (http://programme. aids2018.org/Abstract/Abstract/8205, consulté le 18 mars 2020).
123. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis. 1962;86:810–22.
124. Shanaube K, Sismanidis C, Ayles H, Beyers N, Schaap A, Lawrence K-A, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS ONE. 2009;4(11):e7749.
125. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827–30.
126. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int Union Tuberc Lung Dis. 1999;3(10):847–50.
127. Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 1999 (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858. CD001363/full, consulté le 18 mars 2020).
128. Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine WL, Charalambous S, Martinson NA, Yimer G. Effectiveness of 3HP annually vs. once for HIV-positive people: the WHIP3TB trial. In: TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HIV TESTING. Boston, Massachusetts, USA; 2020. (https://www.croiconference.org/sessions/effectiveness-3hp-annually-vs-once-hiv-positive-peoplewhip3tb- trial, consulté le 18 mars 2020).
129. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–51.
130. den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8): 1065–1071.
131. van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24(7):1051.
132. Bonnes pratiques de soins pour les patients atteints de tuberculose. Guide pour les pays à faibles revenus. 2ème édition. Paris : Union internationale contre la tuberculose et les maladies respiratoires ; 2017. (https:// www.theunion.org/what-we-do/publications/technical/french/TB-Best-Practice-Guide-Union-French.pdf, consulté le 18 mars 2020).
133. Lutge EE, Wiysonge CS, Knight SE, Sinclair D, Volmink J. Incentives and enablers to improve adherence in tuberculosis. Cochrane Database Syst Rev. 2015;(9):CD007952. doi: 10.1002/14651858.CD007952.pub3.
134. Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational Interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–40.
135. Ethics guidance for the implementation of the End TB Strategy. Geneva: World Health Organization; 2017 (http://www.who.int/tb/publications/2017/ethics-guidance/en/, consulté le 18 mars 2020).
136. Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology. 2010;15(4):603–22.
137. Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV – no more excuses. Lancet Glob Health. 2017;5(11):e1048–9.
138. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. Morb Mortal Wkly Rep. 2018;67(25):723–6.
139. TB elimination. Tuberculin skin testing. Atlanta: Centre for Disease Control and Prevention; 2011 (https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf, accessed 18 March 2020).
140. Morán-Mendoza O, Tello-Zavala MC, Rivera-Camarillo M, Ríos-Meza Y. Comparison of different methods and times for reading the tuberculin skin test. Int J Tuberc Lung Dis. 2013;17(10):1273–8.
141. Zahrani KA, Jahdali HA, Menzies D. Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. Am J Respir Crit Care Med. 2000;162(4):1419–22.
142. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5.
143. Chaturvedi N, Cockcroft A. Tuberculosis screening in health service employees: who needs chest X-rays? Occup Med. 1992;42(4):179–82.
144. Starke JR. Tuberculosis skin testing: new schools of thought. Pediatrics. 1996;98(1):123–5.
145. Nayak S, Acharjya B. Mantoux test and its interpretation. Indian Dermatol Online J. 2012;3(1):2–6.
146. Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep. 2000;49(RR06):1–54.
147. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle. 1966;47(3):308.
148. Veening GJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc. 1968;41:169–71.
149. Rothel JS, Jones SL, Corner LA, Cox JC, Wood PR. A sandwich enzyme immunoassay for bovine interferon-g and its use for the detection of tuberculosis in cattle. Aust Vet J. 1990;67(4):134–7.
150. Converse PJ, Jones SL, Astemborski J, Vlahov D, Graham NMH. Comparison of a tuberculin interferon-g assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis. 1997;176(1):144–50.
151. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis. 1998;2(6):443–50.
152. Kay AW, Islam SM, Wendorf K, Westenhouse J, Barry PM. Interferon-g release assay performance for tuberculosis in childhood. Pediatrics. 2018;141(6):e20173918.
